Do domperidone and Lyrica (pregabalin) need to be tapered when discontinuing?

Tapering Requirements for Domperidone and Pregabalin (Lyrica)

Direct Answer

Yes, both domperidone 10 mg BID and Lyrica (pregabalin) 50 mg BID require tapering when discontinuing—pregabalin must be tapered per FDA labeling to minimize withdrawal symptoms, and domperidone should be tapered based on emerging evidence of psychiatric withdrawal manifestations. 1, 2

---

Pregabalin (Lyrica) 50 mg BID - REQUIRES TAPERING

FDA-Mandated Tapering Protocol

The FDA drug label explicitly states that pregabalin must be tapered gradually over a minimum of 1 week rather than discontinued abruptly. 1

• Withdrawal symptoms following abrupt discontinuation include: insomnia, nausea, headache, anxiety, hyperhidrosis (excessive sweating), and diarrhea 1
• The FDA warning specifically states there is an "increased risk of adverse reactions with abrupt or rapid discontinuation" 1
• For patients with seizure disorders, gradual withdrawal is critical to minimize the potential of increased seizure frequency 1

Recommended Tapering Approach

Based on Mayo Clinic guidelines for calcium channel α2-δ ligands (pregabalin class), taper by reducing approximately 25% of the current dose every 1-2 weeks. 3

• At 50 mg BID (100 mg/day total), reduce to 75 mg/day for 1-2 weeks, then to 50 mg/day for 1-2 weeks, then to 25 mg/day for 1-2 weeks before complete discontinuation 3
• The taper duration should be individualized based on tolerance to dose reductions—patients on higher doses or longer duration of therapy may require slower tapers 3
• Monitor closely for return of neuropathic pain symptoms during the taper 3

Critical Monitoring During Pregabalin Taper

• Schedule follow-up appointments at least monthly during the tapering process 3
• Watch for withdrawal symptoms (anxiety, insomnia, gastrointestinal symptoms) that signal the need to slow the taper further 3
• Be aware that dizziness and somnolence (which affect 30% and 23% of patients respectively during treatment) may persist until the last dose 1

---

Domperidone 10 mg BID - REQUIRES TAPERING

Evidence for Tapering Requirement

While domperidone lacks formal FDA approval in the US and official tapering guidelines, emerging case reports demonstrate significant psychiatric withdrawal symptoms upon discontinuation, particularly when used at higher doses for lactation. 2, 4

• Three documented US cases showed psychiatric withdrawal symptoms lasting months during tapering and after cessation of domperidone used as a galactagogue 2
• A case report documented recurrence of major depressive disorder and OCD symptoms after abrupt domperidone discontinuation, which improved with drug reinitiation and gradual taper 4
• These psychiatric manifestations are clinically distinct from postpartum depression and represent true withdrawal phenomena 2

Recommended Tapering Approach for Domperidone

A slow hyperbolic taper is suggested to minimize withdrawal symptoms, though optimal tapering protocols remain unstudied. 2

• At 10 mg BID (20 mg/day), consider reducing by 25% every 1-2 weeks: reduce to 15 mg/day for 1-2 weeks, then 10 mg/day for 1-2 weeks, then 5 mg/day for 1-2 weeks before discontinuation 2, 4
• Dutch guidelines classify domperidone among drugs acting on the central nervous system that cause severe withdrawal symptoms when stopped abruptly, requiring gradual tapering 5
• Abrupt discontinuation should be avoided, as it may precipitate psychiatric symptoms including anxiety, depression, and obsessive-compulsive features 2, 4

Special Considerations for Domperidone

• Patients may be hesitant to disclose domperidone use (particularly when obtained from non-US sources), which can delay recognition of withdrawal symptoms 2
• Withdrawal manifestations are commonly confused with postpartum depression in lactating mothers, leading to inappropriate treatment 2
• The risk may be dose-dependent, with higher doses used for lactation (often exceeding studied on-label indications) posing greater withdrawal risk 2

---

Common Pitfalls to Avoid

• Never discontinue pregabalin abruptly—this violates FDA labeling and risks withdrawal syndrome 1
• Do not assume domperidone can be stopped without tapering simply because it lacks US FDA approval—case evidence demonstrates real withdrawal risk 2, 4
• Avoid mistaking withdrawal symptoms for recurrence of the original condition or new psychiatric illness 2, 6
• Do not use fixed short tapers (2-4 weeks to therapeutic minimum doses)—these show minimal benefit over abrupt discontinuation for many psychotropic medications 7
• If withdrawal symptoms emerge during tapering, slow the taper rate further rather than returning to the full dose 3, 1

---

Clinical Algorithm for Discontinuation

1. Assess duration of therapy and current dose for both medications 3
2. Initiate pregabalin taper first (minimum 1 week, preferably longer) with 25% dose reductions every 1-2 weeks 1
3. Once pregabalin is discontinued, begin domperidone taper using similar 25% reductions every 1-2 weeks 2, 4
4. Schedule monthly follow-up appointments throughout both tapers to monitor for withdrawal symptoms and symptom recurrence 3
5. If withdrawal symptoms emerge, pause the taper and maintain the current dose for an additional 1-2 weeks before attempting further reduction 3, 1